Business
Dutch Bros opens in Southern California
(Paul Bersebach/Getty Images)

America’s fast-food scene had some big winners, and even bigger losers, in Q2 2025

Taco Bell is beating Chipotle, Dutch Bros is crushing Starbucks, and the chicken wars are fiercer than ever.

Much was made of America’s inflation-weary fast-food consumers becoming more price conscious over the last few years.

Now, with Q2 in the rearview mirror, we can ask: which fast-food chains are winning in America?

Let’s start with the biggest in the game. McDonald’s actually had a great quarter, with the Golden Arches posting year-on-year same-store sales growth of 2.5% in the US, digging the Big Mac maker out of a hole after a lackluster year of declines. That was significant considering that the company’s execs characterized the quarter as “challenging,” as visits across the industry by low-income consumers declined by “double-digit” percentages.

Value option Taco Bell put up even better numbers, with same-store sales up 4% — crushing Chipotle in the Mexican-inspired scene as its more expensive competitor struggles to lure customers back for burritos and bowls, with same-store sales dropping 4% year on year.

Fast food growth
Sherwood News

Topping the list, however, was coffee chain Dutch Bros, where same-store sales rose 6.1% — perhaps benefiting from the difficulties at coffee giant Starbucks, which continues to invest heavily in a bid to reinvigorate the “coffeehouse experience.”

Elsewhere, with consumers’ love for chicken inspiring an entire generation of entrepreneurs to enter the chicken wars, the competition in all things wings has never been more intense — and it seems to be weighing on Yum! Brands’ KFC, where sales dropped 5%. But no company had a worse quarter than fast-casual salad chain Sweetgreen, where revenue resembled spinach being cooked: store sales shrunk a whopping 7.6% in the latest quarter.

Related reading: Battle of the sad desk lunches: Both Cava and Sweetgreen want to become the next Chipotle

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.